CROES Registry
Prostate Cancer
Post-Market RegistryActive
Key Facts
About AngioDynamics
AngioDynamics is a publicly traded medical device company with a mission to improve patient lives by providing innovative, minimally invasive tools for treating peripheral vascular disease and cancer. The company has strategically evolved from a broad vascular access provider into a focused innovator, building a diversified technology portfolio through R&D and acquisitions. Its current strategy centers on commercializing and expanding the clinical evidence for its three core platforms—Auryon, AlphaVac, and NanoKnife—while navigating a competitive landscape and managing the financial and operational challenges of a mid-cap device maker.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO442 | Aptevo Therapeutics | Preclinical |
| APVO452 | Aptevo Therapeutics | Discovery |
| BIO 300 | Humanetics Corp. | Not Specified |
| Opaganib | RedHill Biopharma | Phase 2 |
| Small-Molecule Therapeutic | AIkido Labs | Pre-clinical |
| Leronlimab | CytoDyn | Preclinical |
| Cannabics® PRST-33 | CNBX Pharmaceuticals | Discovery |
| HDP-103 | Heidelberg Pharma | Preclinical |
| ENV105 | Kairos Pharma | Phase 2 |
| AI for Prostate Cancer | Invenio Imaging | Research |
| Mitomic™ Test for Prostate Cancer | MDNA Life Sciences | Development/Validation |
| Immunomodulator Platform | OmniCyte | Research |